• The recombinant Chinese measles virus vaccine strain rMV-Hu191 induced efficient infection and oncolytic effects in human CRC both in vitro and in vivo. • rMV-Hu191 induced the caspase-dependent apoptosis and complete autophagy in CRC cells. • Autophagy served as a protective role in human CRC cells’ apoptosis induced by rMV-Hu191. • rMV-Hu191-induced autophagy and apoptosis were regulated by the PI3K/AKT signaling pathway in human CRC.
Background: DDP-based chemotherapy is one of the first-line treatment in GC. However, the therapeutic efficacy of DDP is limited due to side effects. Therefore, it is of great significance to develop novel adjuvants to synergize with DDP. We had demonstrated previously that rMV-Hu191 had antitumor activity in GC. Here we examined the synergism of rMV-Hu191 with DDP in vitro and in vivo.Methods: Cellular proliferation, the synergistic effect and cell apoptosis were evaluated by CCK-8 assay, ZIP analysis and flow cytometry, respectively. The protein levels and location of ASMase were monitored by western blot and immunofluorescence assay. shRNA and imipramine were used to regulate the expression and activity of ASMase. MβCD was administrated to disrupt lipid rafts. Mice bearing GC xenografts were used to confirm the synergism in vivo.Results: From our data, combinational therapy demonstrated synergistic cytotoxicity both in resistant GC cell lines from a Chinese patient and drug-nonresistant GC cell lines, and increased cell apoptosis, instead of viral replication. Integrity of lipid rafts and ASMase were required for rMV-Hu191- and combination-induced apoptosis. The ASMase was delivered to the lipid raft microdomains at the initial stage of rMV-Hu191 treatment. In vivo GC mice xenografts confirmed the synergism of combinational treatment, together with increased apoptosis and trivial side-effects.Conclusions: This is the first study to demonstrate that rMV-Hu191 combined with DDP could be used as a potential therapeutic strategy in GC treatment and the ASMase and the integrity of lipid rafts are required for the synergistic effects.
Oncolytic virotherapy (OVT) is a promising anticancer strategy, owing to its capacity to lyse tumor cells selectively and remodel the tumor microenvironment (TME) to enhance antitumor efficacy. Despite the continuous introduction and investigation of newly engineered oncolytic viruses (OVs) in clinical trials, their clinical translation remains limited, with Toll-like receptor (TLR)-mediated host immune responses representing a critical influencing factor. TLRs constitute a family of structurally conserved transmembrane proteins distributed on the plasma membrane and endosomal membranes. They initiate innate immune responses by recognizing pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) and are essential for dendritic cells (DCs) maturation, playing a pivotal regulatory role across diverse tumor therapies. However, TLRs may also restrict viral replication and spread, and some studies suggest that they could, under certain conditions, act as drivers of tumor progression. Nonetheless, the role of TLRs in OVT has not been comprehensively summarized to date. In this review, we synthesize recent advances in the application of TLRs in OVT, with particular attention to their mechanisms of action and the challenges that remain to be overcome, and consider their prospects in oncology, offering insights that may inform the clinical translation of this therapeutic approach.